New Delhi: Drug major Sun Pharmaceutical Industries is expected to post high single-digit revenue growth in the current financial year, according to managing director Dilip Shanghvi.
The Mumbai-based firm reported a consolidated total revenue from operations of Rs 48,497 crore for FY2014. In FY23 this number was Rs 43,886 crore.
"We expect high single-digit consolidated revenue growth for fiscal 2025. All of our businesses are poised for growth," Sanghvi said in an analyst call.
He said the pharmaceutical company will be in the investment phase for many of its businesses in the current financial year.
“This includes, but is not limited to, product launch costs in the US, as our global specialty business is expected to continue to accelerate,” Sanghvi said.
He said R&D investment during the year would be 8-10 percent of sales.
Responding to a separate question, Shanghvi said, "We have to continue to invest for the future. And our endeavor will be that when we are investing for the future, we should not do it at the cost of profitability."
He added, "But even if it requires some increased investment, we will do it because ultimately, our focus is on building a business that is strong in the long term."
According to the AIOCD AWACS MAT March 2024 report, Sun Pharma is ranked number one and holds 8.5 percent market share in the Indian pharmaceutical market worth over Rs 1,970 billion.
For the financial year ending March 31, 2024, the company reported a consolidated net profit of Rs 9,576 crore. In the financial year 2022-23 it stood at Rs 8,474 crore.
The Mumbai-based firm reported a consolidated total revenue from operations of Rs 48,497 crore for FY2014. In FY23 this number was Rs 43,886 crore.
"We expect high single-digit consolidated revenue growth for fiscal 2025. All of our businesses are poised for growth," Sanghvi said in an analyst call.
He said the pharmaceutical company will be in the investment phase for many of its businesses in the current financial year.
“This includes, but is not limited to, product launch costs in the US, as our global specialty business is expected to continue to accelerate,” Sanghvi said.
He said R&D investment during the year would be 8-10 percent of sales.
Responding to a separate question, Shanghvi said, "We have to continue to invest for the future. And our endeavor will be that when we are investing for the future, we should not do it at the cost of profitability."
He added, "But even if it requires some increased investment, we will do it because ultimately, our focus is on building a business that is strong in the long term."
According to the AIOCD AWACS MAT March 2024 report, Sun Pharma is ranked number one and holds 8.5 percent market share in the Indian pharmaceutical market worth over Rs 1,970 billion.
For the financial year ending March 31, 2024, the company reported a consolidated net profit of Rs 9,576 crore. In the financial year 2022-23 it stood at Rs 8,474 crore.
